Skip to main content

BEAM

Stock

BEAM

Stock
Health Care
Biotechnology

Performance overview

BEAM Price
Price Chart

Forward-looking statistics

Beta
1.56
Risk
69.77%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Company info

SectorHealth Care
IndustryBiotechnology
Employees504
Market cap$1.9B

Fundamentals

Enterprise value$596.4M
Revenue$63.6M
Revenue per employee
Profit margin0.00%
Debt to equity14.08

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.61
Dividend per share
Revenue per share$0.76
Avg trading volume (30 day)$40M
Avg trading volume (10 day)$44M
Put-call ratio

Macro factor sensitivity

Growth+7.3
Credit+6.2
Liquidity-4.8
Inflation+3.6
Commodities+2.7
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio-4.19
Price to sales31.65
P/E Ratio-4.19
Enterprise Value to Revenue9.38
Price to book1.74

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend day

News

Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?

Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research (July 10, 2025)
3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

Zacks Investment Research (June 27, 2025)
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing.

Benzinga (March 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free